|Bid||135.00 x 300|
|Ask||135.12 x 100|
|Day's Range||134.86 - 137.64|
|52 Week Range||96.18 - 145.42|
|PE Ratio (TTM)||64.65|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.